A Covid-19 vaccine being developed by CSL Ltd. and the University of Queensland was scrapped after numerous vaccine recipients reported receiving false positives on certain HIV tests, according to the Wall Street Journal.
Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
The U.S. Food and Drug Administration approved Kala Pharmaceuticals’ Eysuvis for the short-term treatment of dry eye disease.
U.S-based cancer testing startup Grail Inc., a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) with the U.S. Securities and Exchange Commission.
RegeneRx Biopharmaceuticals Inc. announced that a multi-institutional team of scientists from eight American research centers published a research paper on new therapeutic approaches for Covid-19 in which they propose that Thymosin beta 4 (Tβ4), because of its ability to induce fibrinolysis, among other activities, may be useful in treating patients with the Covid-19 virus.
Researchers said a fresh examination showed a malformation on a Centrosaurus was a manifestation of osteosarcoma, an aggressive bone cancer, making this the first known example of a dinosaur afflicted by malignant cancer.
Atox Bio had positive results in the company’s Phase III ACCUTE trial for reltecimod for early treatment of severe Necrotizing Soft Tissue Infection (NSTI), a so-called flesh-eating disease.
The U.S. Food and Drug Administration granted approval of Endo International’s Qwo (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women. QWO is the first FDA-approved injectable treatment for cellulite.
Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
Epizyme’s oral potent, first-in-class EZH2 inhibitor tazemetostat won accelerated approval from the U.S. Food and Drug Administration for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.